On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...
Risk for pancreatitis was not elevated among users of tirzepatide relative to placebo, despite the presence of elevated pancreatic enzymes.
(Yicai) Jan. 3 -- US pharma giant Eli Lilly’s Tirzepatide injection for blood sugar control and weight loss is now available ...
Tirzepatide is approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, alongside diet and exercise. The SURMOUNT-OSA trial showed significant reductions in breathing ...
Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...
If you’re starting a weight loss journey, you might have stumbled upon tirzepatide — the drug approved by the FDA (U.S. Food and Drug Administration) under the brand names Mounjaro and Zepbound.
The ITC found that "multiple bad actors" have been importing or selling knockoff copies of Lilly's tirzepatide.
After a second investigation, the FDA announced tirzepatide will no longer be on the agency’s drug shortage list. Dates were announced for distribution of compounded forms for the drugs to end.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback